Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Brazil's Ouro Fino Saúde Animal has got a growth plan that brings internationalization and vaccines to the fore. The firm's Kleber Gomes (chief financial officer) and Ricardo Teles (business development manager) spoke about strategy to Animal Pharm correspondent Ana Andrade at the recent Animal Health Innovation Latin America conference in São Paulo.
The USDA's Animal and Plant Health Inspection Service (APHIS) continues to work on implementing provisions in the 2018 Farm Bill dealing with animal health issues.
Dutch start-up BunyaVax will provide its technology to a consortium developing a human Rift Valley fever (RVF) vaccine.
European authorities have approved MSD Animal Health's Bravecto Plus (fluralaner/moxidectin) for the treatment of ear mites in cats.
The UK's National Office of Animal Health (NOAH) has found Boehringer Ingelheim to be in breach of code on its promotion of a cattle vaccine.
In light of the spread of African swine fever (ASF) in Europe and Asia, Animal Pharm editor Joseph Harvey spoke to someone who has lengthy experience in vaccine development from both a research and commercial perspective. Jeremy Salt – GALVmed's chief scientific officer – gave his viewpoint on how close the industry might be to an ASF preventative.
A grant program at Alabama's Auburn University is funding a project focused on a respiratory disease in calves.
Zoetis has recently gained approvals for different formulations within its Fostera swine vaccine portfolio.
Swedish business Intervacc has finalized production of its vaccine for equine strangles on a commercial scale.
Laboratorios Hipra has continued its expansion across Asia with the introduction of Vepured to the Thai swine market.
Elanco has significantly bolstered its swine vaccine portfolio by acquiring Canadian company Prevtec Microbia.
US start-up Man's Best Friend Therapeutics (MBFT) has enhanced development of its immunotherapeutic treatments by signing an exclusive option agreement with the University of North Carolina (UNC).
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.